HOUSTON, May 01, 2017 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP ) (“PLx”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), announced the appointment of industry veteran and commercial leader, Michael J. Dillon as Vice President, Sales and Marketing effective today.
This strategic hire supports the forthcoming launch of Aspertec, an aspirin product with antiplatelet efficacy clinically demonstrated to provide improved reliability and predictability.
“Mike is an extremely talented and innovative sales and marketing leader whose expertise in successfully launching products and consistent track record of building high-performing Cardiovascular and Central Nervous System sales forces are relevant as we prepare for the commercial launch of Aspertec, our differentiated, next-generation aspirin product, and transition to a commercial-stage company,” stated Natasha Giordano, President and Chief Executive Officer of PLx.
“Mike’s diverse cross-functional experience in marketing, operations and sales and management training will help drive PLx’s commercial success. I am delighted to welcome him to the PLx management team and look forward to his contributions,” added Giordano.
An accomplished business leader, Mr. Dillon brings over 20 years of experience in driving performance and developing colleagues to achieve their goals. His proven track record includes success in building high-performing, cross-functional specialty sales teams to compete and win in diverse markets.
Mr. Dillon joins PLx from Publicis Healthcare Communications Group, a leading commercialization partner to pharmaceutical and biotech companies globally. During his six-year tenure as National Sales and Operations Director, he led successful new product launches for multiple start-up companies.
Prior to Publicis, Mr. Dillon spent 17 years at Pfizer in increasingly senior sales and marketing positions across the organization, including New York Regional Sales Director; New Jersey Regional Sales Director, Neuroscience Division; and National Sales and Operations Director.
While at Pfizer, Mr. Dillon launched key, best in class brands such as Lipitor & Lyrica; designed and implemented successful national marketing campaigns; and led top-performing teams to exceed company sales forecast and goals.
Mr. Dillon earned a Bachelor of Science degree in Business Administration with a concentration in Marketing from the State University of New York. He also attained a Leadership Certification (General Management & Strategic Planning) from Wharton Business School and University of Texas McCombs School of Business.
About Aspertec Aspertec is an FDA approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.
About PLx Pharma Inc. PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide safe and effective aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com .
Forward Looking Statements Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks related to any litigation or post-closing disputes arising out of matters related to PLx’s merger with Dipexium; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property and risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Other risks and uncertainties are more fully described in Dipexium’s Registration Statement on Form S-4 filed with the SEC, and in other filings that PLx will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.
Contact Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Media: Ann Smith, Coyne Public Relations T: 973-588-2385 E: asmith@coynepr.com
